GLP-1 Medications

Ozempic, semaglutide, tirzepatide and the GLP-1 class — what SGV’s teachers say about strength, muscle loss, low-dosing, alternatives and the research frontier.

This hub is part of the SGV peptide library — start at the Peptides topic hub for the full map. Everything below is a roundup of what the teachers in this library say in their own videos, in their own words and framing. Claims belong to the speakers; SGV draws no medical conclusions, and nothing here is dosing or sourcing guidance — it is a guide to the conversation.

The strength debate: semaglutide vs. tirzepatide

The most argued question in the class is which drug is “stronger.” In Semaglutide Is Stronger Than Tirzepatide?, Dr. Kyle Gillett and James O’Hara challenge the common claim that tirzepatide is simply stronger, arguing that potency comparisons are meaningless without accounting for the dose being compared, and that headline charts can mislead. Nathalie Niddam walks the same comparison from the mechanism side in Fat Loss Peptides Deep Dive: Semaglutide vs. Tirzepatide Explained, explaining how one medicine acts mainly through a single gut-hormone pathway while the other adds a second — and stressing that clinician supervision is essential rather than optional.

Starting, tolerating, and staying on

In Is Semaglutide Right For You?, Gillett names nausea as the main downside to plan around and describes, at a general level, how clinicians soften it by starting lower and raising the dose more slowly than trial protocols do. Dr. Elizabeth Yurth makes the usage argument in WATCH THIS Before You Use Ozempic: in her account, many problems blamed on the drug stem from how it is used — obtained without nutrition, hydration or eating-adequacy coaching — and her preferred approach is gradual and individualized.

The warning that repeats: muscle

Two teachers independently put muscle at the center. Dr. Gabrielle Lyon argues in Future of GLP1s like Ozempic that while she describes these drugs as highly effective tools, a significant portion of the weight lost may be lean muscle rather than fat — and that treatment must prioritize resistance training and adequate protein, or users risk trading one health problem for another. Gary Brecka sounds the same alarm in The GLP-1 Side Effect Nobody Warns You About, claiming that a substantial share of weight lost in some studies was lean mass, and arguing prescribers should pair the drugs with protein intake and resistance training.

The midlife-women lens

Jennifer Woodward’s library covers the class through perimenopause and menopause. In How Low-Dosing GLP-1s Actually Work for Midlife Women, registered nurse Jacquie Anderson shares her clinical experience with GLP-1s and hormone therapy for midlife women, including her own story after an early hysterectomy. In The GLP-1 Crackdown, Microdosing, and the Future of Metabolic Health, Dr. Dean Jones discusses the regulatory enforcement that shut down many research peptide suppliers and how his own view of long-term use has evolved.

Alternatives and adjuncts

For people who cannot access, tolerate, or prefer to avoid the prescription drugs, Niddam surveys alternatives in Should You Stop Using Ozempic & Use These Peptides for Weight Loss Instead? — while repeatedly stressing, in her training-wheels analogy, that gentler options demand more lifestyle effort and that diet quality remains foundational either way. (Disclosure, as on her page: that episode discusses specific commercial products sold through her recommendation channels.)

The research frontier — and a skeptic’s check

Dr. William Seeds dissects a much-shared preprint in Ep.26 — The Latest Clinical Study on GLP 1 Receptor Agonists, in which semaglutide was reported to slow epigenetic aging markers. Seeds stresses the paper is not yet peer-reviewed and aims most of his skepticism at epigenetic clocks themselves — a useful reminder that in this library, the teachers fact-check each other’s enthusiasms too.

A personal account

Derek of More Plates More Dates documents his own experience in Losing Over 50 POUNDS With GLP-1 Agonists — one practitioner’s n-of-1, presented as his account, not a protocol.

Sidebar: tesamorelin — the “what’s next” conversation

Tesamorelin comes up in this library mainly as a follow-on question: what do people consider after GLP-1 treatment? Woodward’s What’s Next After GLP-1? NAD+, Tesamorelin & Peptide Stacking for Midlife Energy & Muscle follows two guests from GLP-1 agonists into stacking additional compounds, with the guests emphasizing that lifestyle factors remain foundational to their reported outcomes. Coverage is thin — a handful of episodes across Woodward and Niddam — so it lives here as a sidebar rather than its own hub.

Go deeper by teacher

• Dr. Kyle Gillett’s videos — the deepest GLP-1 bench in the library
• Jennifer Woodward’s videos — GLP-1s and midlife women; see also her FDN practitioner guide
• Nathalie Niddam’s videos
• Dr. Gabrielle Lyon’s videos — the muscle-first case
• Dr. William Seeds’ videos
• Dr. Elizabeth Yurth’s videos
• Gary Brecka’s videos
• Derek’s videos

Related compound hubs: BPC-157 · TB-500 · GHK-Cu · All peptides